AB Science has received a U.S. patent for masitinib in treating sickle cell disease (SCD), with protection extending to 2040. The approval follows compelling preclinical results showing masitinib’s efficacy against severe SCD forms (65% of cases), where it prevented vaso-occlusive crises and death in mouse models — 83% of untreated mice died within 3 hours versus 0% in treated groups. The drug also reduced lung injury and mast cell infiltration, key drivers of SCD complications. Masitinib is now advancing in phase 2 trials under the €9.2M SICKMAST program, offering a promising alternative to current limited treatments (hydroxyurea, transfusions) and inaccessible gene therapies.

At OxyDial, we see this as a transformative step for SCD care. Masitinib’s extended patent and novel mast cell-targeting approach could address critical gaps in treating severe cases, aligning with our commitment to advancing hematology innovations that improve patient outcomes.

Read more: https://www.marketscreener.com/quote/stock/AB-SCIENCE-6133795/news/AB-Science-SA-Receives-Notice-of-Allowance-for-Unites-States-Patent-Covering-Masitinib-Until-2040-in-49614397/

#SickleCellDisease #Hematology #MedicalBreakthrough #Masitinib #BloodDisorders #OxyDial #PatientCare